X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS AUROBINDO PHARMA DR. DATSONS LABS/
AUROBINDO PHARMA
 
P/E (TTM) x -10.9 14.6 - View Chart
P/BV x 0.2 3.8 4.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 DR. DATSONS LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA
Mar-17
DR. DATSONS LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126895 14.0%   
Low Rs31622 5.0%   
Sales per share (Unadj.) Rs133.0254.6 52.2%  
Earnings per share (Unadj.) Rs0.239.3 0.4%  
Cash flow per share (Unadj.) Rs6.646.6 14.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs128.8160.0 80.5%  
Shares outstanding (eoy) m31.66585.88 5.4%   
Bonus/Rights/Conversions FCCBESOP-  
Price / Sales ratio x0.63.0 19.7%   
Avg P/E ratio x516.119.3 2,672.7%  
P/CF ratio (eoy) x11.816.3 72.7%  
Price / Book Value ratio x0.64.7 12.8%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m2,477444,390 0.6%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m5617,678 0.3%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m4,211149,157 2.8%  
Other income Rs m791,159 6.8%   
Total revenues Rs m4,289150,316 2.9%   
Gross profit Rs m56934,343 1.7%  
Depreciation Rs m2044,276 4.8%   
Interest Rs m430667 64.5%   
Profit before tax Rs m1330,558 0.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67,597 0.1%   
Profit after tax Rs m523,012 0.0%  
Gross profit margin %13.523.0 58.7%  
Effective tax rate %48.024.9 193.2%   
Net profit margin %0.115.4 0.7%  
BALANCE SHEET DATA
Current assets Rs m6,85292,062 7.4%   
Current liabilities Rs m6,71166,223 10.1%   
Net working cap to sales %3.317.3 19.3%  
Current ratio x1.01.4 73.4%  
Inventory Days Days161106 151.8%  
Debtors Days Days31868 470.6%  
Net fixed assets Rs m3,67362,919 5.8%   
Share capital Rs m317586 54.0%   
"Free" reserves Rs m3,76193,133 4.0%   
Net worth Rs m4,07893,719 4.4%   
Long term debt Rs m1,6711,814 92.1%   
Total assets Rs m12,633162,494 7.8%  
Interest coverage x1.046.8 2.2%   
Debt to equity ratio x0.40 2,117.0%  
Sales to assets ratio x0.30.9 36.3%   
Return on assets %3.414.6 23.6%  
Return on equity %0.124.6 0.5%  
Return on capital %7.732.7 23.4%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96475,838 1.3%   
Fx outflow Rs m60730,224 2.0%   
Net fx Rs m35745,613 0.8%   
CASH FLOW
From Operations Rs m1,34532,786 4.1%  
From Investments Rs m-2,256-17,870 12.6%  
From Financial Activity Rs m-1,200-19,153 6.3%  
Net Cashflow Rs m-2,111-4,239 49.8%  

Share Holding

Indian Promoters % 4.5 54.1 8.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 1.4 27.7 4.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.2 922.5%  
Shareholders   20,807 69,601 29.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

Mahindra Logistics Ltd. (IPO)

Oct 28, 2017

Should you subscribe to the IPO of Mahindra Logistics Ltd?

Godrej Agrovet Ltd. (IPO)

Oct 4, 2017

Should you subscribe to the IPO of Godrej Agrovet Limited?

Matrimony.com (IPO)

Sep 11, 2017

Should you subscribe to the IPO of Matrimony.com?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS